Fiche publication
Date publication
septembre 2021
Journal
The Journal of investigative dermatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSUSSAN Armand
Tous les auteurs :
Habault J, Thonnart N, Pasquereau-Kotula E, Bagot M, Bensussan A, Villoutreix BO, Marie-Cardine A, Poyet JL
Lien Pubmed
Résumé
Sézary syndrome is an aggressive form of cutaneous T-cell lymphoma characterized by the presence of a malignant CD4 T-cell clone in both blood and skin. Its pathophysiology is still poorly understood, and the development of targeted therapies is hampered by the absence of specific target proteins. AAC-11 plays important roles in cancer cell progression and survival and thus has been considered as an anticancer therapeutic target. In this study, we show that a peptide called RT39, comprising a portion of AAC-11‒binding site to its protein partners coupled to the penetratin sequence, induces the specific elimination of the malignant T-cell clone both ex vivo on the circulating cells of patients with Sézary syndrome and in vivo in a subcutaneous xenograft mouse model. RT39 acts by direct binding to PAK1 that is overexpressed, located in the plasma membrane, and constitutively activated in Sézary cells, resulting in their selective depletion by membranolysis. Along with the absence of toxicity, our preclinical efficacy evidence suggests that RT39 might represent a promising alternative therapeutic tool for Sézary syndrome because it spares the nonmalignant immune cells and, contrary to antibody-based immunotherapies, does not require the mobilization of the cellular immunity that shows heavy deficiencies at advanced stages of the disease.
Mots clés
Animals, Apoptosis Regulatory Proteins, genetics, CD4-Positive T-Lymphocytes, immunology, Carcinogenesis, Cell-Penetrating Peptides, metabolism, Clone Cells, Gene Expression Regulation, Neoplastic, Heterografts, Humans, Mice, Nuclear Proteins, genetics, Peptides, genetics, Protein Binding, Sezary Syndrome, therapy, Skin Neoplasms, therapy, p21-Activated Kinases, genetics
Référence
J Invest Dermatol. 2021 09;141(9):2261-2271.e5
